Skip Navigation


eCAM Advance Access originally published online on October 27, 2004
eCAM 2004 1(3):285-289; doi:10.1093/ecam/neh045
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
1/3/285    most recent
neh045v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Murayama, T.
Right arrow Articles by Eizuru, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murayama, T.
Right arrow Articles by Eizuru, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2004, the authors Evidenced-based Complementary and Alternative Medicine, Vol. 1, Issue 3 © Oxford University Press 2004; all rights reserved. The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated.

In Vitro Anti-Cytomegalovirus Activity of Kampo (Japanese Herbal) Medicine

Tsugiya Murayama1,*, Nobuo Yamaguchi2, Hideo Matsuno2 and Yoshito Eizuru1

1Division of Persistent and Oncogenic Viruses, Center for Chronic Viral Disease, Graduate School of Medical and Dental Sciences, Kagoshima University Kagoshima 890-8520, Japan, and 2Department of Serology, Kanazawa Medical University Uchinada, Ichikawa 920-0293, Japan

We examined the effect of three types of Kampo medicines on human cytomegalovirus (CMV) replication in the human embryonic fibroblast cell line, MRC-5. Treatment of cells with at least 0.01 µg/ml of Kampo medicines inhibited the cytopathic effects of CMV-infected MRC-5 cells. Moreover, Kampo medicine decreased the replication of CMV without affecting the inhibition of host cells, with a concomitant decrease in CMV DNA levels. However, Kampo medicine demonstrated no virocidal effect on cell-free CMV. Furthermore, western blotting analysis demonstrated that the Kampo medicine decreased the amount of 65 kDa late antigen expression in the infected cells. These results suggest that Kampo medicine may be sufficient to inhibit viral DNA replication and late protein synthesis, resulting in anti-CMV effects. Therefore, these three Kampo medicines have the potential of being a source of new powerful anti-CMV compounds.

Keywords: cytomegalovirus – Kampo medicine – late antigen

*For reprints and all correspondence: Dr Tsugiya Murayama, Division of Persistent and Oncogenic Viruses, Center for Chronic Viral Disease, Faculty of Medicine, Kagoshima University, Kagoshima 890-8520, Japan. Tel: +81-99-275-5936, Fax: +81-99-275-5937,E-mail: t-mura{at}m3.kufm.kagoshima-u.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Evid Based Complement Alternat MedHome page
E. L. Cooper
eCAM: Clinical Analyses and Increasing Visibility
Evid. Based Complement. Altern. Med., March 1, 2009; 6(1): 1 - 2.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.